Health Catalyst, INC Form 4 insider transactions

Director Anita Pramoda acquired 20,807 Restricted Stock Units (RSUs) from Health Catalyst, Inc. on June 13, 2024, according to a Form 4 filing.

Director S. Dawn Smith of Health Catalyst, Inc. was granted 20,807 Restricted Stock Units (RSUs) on June 13, 2024, according to a Form 4 filing.

Jason Alger, CFO of Health Catalyst, Inc., sold 2,823 shares of common stock at a price of $6.83 per share on June 12, 2024, under a pre-arranged trading plan.

Benjamin Landry, General Counsel of Health Catalyst, Inc., sold 2,387 shares of common stock at a price of $6.7105 per share on June 6, 2024, under a pre-arranged 10b5-1 trading plan.

Health Catalyst's Chief Operating Officer, Daniel LeSueur, sold 11,923 shares of common stock at a price of $6.7151 per share on June 6, 2024, according to a pre-arranged trading plan.

Kevin Freeman, Chief Commercial Officer of Health Catalyst, Inc., sold 7,500 shares of common stock at a price of $6.5344 per share on June 11, 2024, according to a Form 4 filing.

Daniel LeSueur, COO of Health Catalyst, sold 1,873 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Linda Llewelyn, Chief People Officer of Health Catalyst, sold 1,716 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Health Catalyst CEO Daniel D. Burton sold 4,442 shares of common stock on June 3, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Jason Alger, CFO of Health Catalyst, Inc., sold 1,238 shares of common stock on June 3, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Kevin Lee Freeman, Chief Commercial Officer of Health Catalyst, sold 2,951 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Benjamin Landry, General Counsel of Health Catalyst, Inc., reports the sale of company stock to cover tax obligations and pursuant to a pre-arranged trading plan.

Linda Llewelyn, Chief People Officer of Health Catalyst, Inc., sold 2,066 shares of common stock at $7 per share on May 15, 2024, under a pre-arranged trading plan.

Linda Llewelyn, Chief People Officer of Health Catalyst, Inc., sold 2,005 shares of common stock at $6.11 per share on April 15, 2024, under a pre-arranged trading plan.

Linda Llewelyn, Chief People Officer of Health Catalyst, Inc., sold 2,005 shares of common stock at a price of $7.8043 per share on March 15, 2024, according to a Form 4 filing.

Health Catalyst's Chief Operating Officer, Daniel LeSueur, reports the acquisition of 70,000 restricted stock units and the sale of 3,279 shares to cover tax obligations.

Benjamin Landry, General Counsel of Health Catalyst, Inc., sold 3,315 shares of common stock on March 1, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Jason Alger, CFO of Health Catalyst, reports the acquisition of 70,000 shares of common stock and the disposal of 2,474 shares to cover tax obligations.

Bryan Truman Hunt, CFO of Health Catalyst, Inc., sold 11,684 shares of common stock on March 1, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Kevin Lee Freeman, Chief Commercial Officer of Health Catalyst, Inc., sold 4,540 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Health Catalyst CEO Daniel D. Burton sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Linda Llewelyn, Chief People Officer of Health Catalyst, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Daniel D. Burton, CEO of Health Catalyst, Inc., reports the acquisition of 26,200 shares of common stock at a price of $7.8063 per share on February 27, 2024.